Alzheimer's disease & dementia

New Alzheimer trial to use epilepsy drug that calms brain activity

What could be one of the first treatments to delay or prevent Alzheimer's disease received a big boost from the National Institute on Aging, which is putting up $7.5 million to help fund the next round of trials for the drug ...

Other

ReWalk receives FDA approval, clearing the way for US sales

There is good news for those suffering from spinal cord injuries. The U.S. Food and Drug Administration gave its stamp of approval to ReWalk—the exoskeleton that enables paraplegics to walk. While the device has sparked ...

Medications

Older pills often safer; many think new is better

Many consumers mistakenly believe new prescription drugs are always safer than those with long track records, and that only extremely effective drugs without major side effects win government approval, according to a new ...

Medications

Pot-based prescription drug looks for FDA OK

A quarter-century after the U.S. Food and Drug Administration approved the first prescription drugs based on the main psychoactive ingredient in marijuana, additional medicines derived from or inspired by the cannabis plant ...

Medications

FDA: Pulmonary embolism risk up with tofacitinib 10 mg for RA

(HealthDay)—A safety clinical trial has revealed that tofacitinib (Xeljanz, Xeljanz XR) 10 mg twice daily is associated with an increased risk for pulmonary embolism (PE) and death among patients with rheumatoid arthritis ...

Oncology & Cancer

New study questions clinical trial data for kidney cancer drugs

When prescribing newly approved drugs, physicians rely on data from clinical trials to understand the benefits and risks of those drugs for patients. But a study published in the Journal of Oncology Practice showed that for ...

page 4 from 18